Nyxoah Expands Commercial Operations With Genio Launch In The Netherlands

Nyxoah has commenced commercial rollout of its Genio bilateral hypoglossal nerve stimulation system in the Netherlands with first implants at OLVG West and Zuyderland Hospital, a key step in its transition to broader commercial operations. Genio, which is leadless, battery-free, externally powered, fully MRI-compatible and stimulates both nerve branches, is positioned to address moderate-to-severe obstructive sleep apnea patients who are intolerant of CPAP and includes an indication for complete concentric collapse; regulatory clearance is supported by the DREAM IDE and BETTER SLEEP trials, CE Mark (2019) and recent FDA approval (August 2025 for a patient subset). Nyxoah expects to expand across Europe via leading centers to accelerate adoption; the stock has traded between $4.34 and $11.87 over the past year, closed at $4.80 (down 0.62%) and was trading up about 6% premarket at $5.10.

Analysis

Nyxoah initiated commercial sales of its Genio hypoglossal nerve stimulation system in the Netherlands with first implants at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen, a milestone the company frames as the start of broader European commercialization. Genio is positioned versus existing implantable devices by being leadless, battery-free, externally powered, fully body MRI‑compatible and stimulating both branches of the hypoglossal nerve, features the company says preserve efficacy in the supine position.

Regulatory support includes a CE Mark from 2019 and a recent FDA approval in August 2025 for a subset of adult moderate‑to‑severe OSA patients; pivotal DREAM IDE and BETTER SLEEP trials and expanded indication for patients with complete concentric collapse underpin the differentiated clinical claim and address a cohort contraindicated for competitor therapies. European and U.S. safety and usability data reported favorable tolerance and surgeon enthusiasm, while Dutch ENT specialists cited the therapy as an alternative for CPAP‑intolerant patients.

Market signals remain early: Nyxoah plans further European rollout via leading centers, the stock traded between $4.34 and $11.87 over the past year, closed at $4.80 (down 0.62%) and was up ~6% premarket at $5.10; independent sentiment outputs are moderately positive with modest projected market impact. Key near‑term value drivers are implant volumes, uptake at partnered centers and the pace of geographic expansion; execution risk and the limited U.S. label are offsetting factors investors should monitor.

Key Decisions for Investors

• Consider a measured, staged exposure to NYXH to capture upside from early European commercial traction while limiting capital at risk,
• Monitor concrete adoption metrics — implant volumes, number and tier of partnered centers, surgeon feedback and patient outcomes — and increase exposure only if these KPIs trend positively,
• Be cautious on U.S. opportunity given FDA approval is limited to a subset of patients; wait for clarity on label expansion before taking a larger U.S.-focused position,
• Manage position risk with disciplined sizing or hedges given historical share volatility and the modest near-term market impact implied by sentiment scores